Rodríguez JV, Martínez C, Durán GM, Villacres MC

Language: Spanish
References: 19
Page: 152-156
PDF size: 256.08 Kb.

ABSTRACT

Onychomycosis, a frequent manifestation in HIV-positive patients, can be used as an indicator of immune function during anti-retroviral treatment.
Objective. to evaluate the presence of onychomycosis in people infected with HIV in an agricultural area of Ecuador.
Methods. HIV patients with suspected onychomycosis were included. Scarification lesion samples were obtained, analyzed by light microscopy and microbiological culture.
Results. 42 subjects were studied, the highest frequency of lesions was observed in the nail plates of the hands than in those of the feet (92.9 versus 7.1% respectively). Trichophyton rubrum and Trichophyton interdigitale were detected in both men and women (60 and 10% for each microorganism), while Candida albicans and Candida spp. detection reached 14 and 10% respectively. In general, multiplicity of microorganisms was observed in samples from women, with a higher frequency of detection of onychomycosis in the hands.
Conclusions. Onychomycosis surveillance can be a simple and inexpensive way to monitor the immune status of patients living with HIV.

REFERENCES

1. Caccavale, S. et al., “The immunocompromised cutaneous district and the necessity of a new classification of its disparate causes”, Indian J Dermatol, venereology and leprology, 2016, 82 (2): 227-229.

2. Lutwak, N. y Dill, C., “Dermatologic manifestations as indicators of immune status in hiv/aids”, J Gen Intern Med, 2012, 27 (7): 765.

3. Muñoz-Pérez, M.A., Rodríguez-Pichardo, A., Camacho, F. y Colmenero, M.A., “Dermatological findings correlated with cd4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse, British J Dermatol, 1998, 139 (1): 33-39.

4. Goldstein, B., Berman, B., Sukenik, E. y Frankel, S.J., “Correlation of skin disorders with cd4 lymphocyte counts in patients with hiv/aids, J Am Acad Dermatol, 1997, 36 (2 Pt 1): 262-264.

5. Dearborn, J.L., Lewis, J. y Mino, G.P., “Preventing mother-to-child transmission in Guayaquil, Ecuador: hiv knowledge and risk perception”, Global Public Health, 2010, 5 (6): 649-662.

6. Park, I.U., Sneed, C.D., Morisky, D.E., Alvear, S. y Hearst, N., “Correlates of hiv risk among Ecuadorian adolescents”, aids Education and Prevention, 2002, 14 (1): 73-83.

7. Beckman, A.L., Wilson, M.M., Prabhu, V., Soekoe, N., Mata, H. y Grau, L.E., “A qualitative view of the hiv epidemic in coastal Ecuador”, Peer J, 2016, 4: e2726.

8. Karaman, B.F.O., Acikalin, A., Unal, I. y Aksungur, V.L., “Diagnostic values of koh examination, histological examination, and culture for onychomycosis: a latent class analysis”, Intern J Dermatol, 2019, 58 (3): 319-324.

9. Lilly, K.K., Koshnick, R.L., Grill, J.P., Khalil, Z.M., Nelson, D.B. y Warshaw, E.M., “Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests”, J Am Acad Dermatol, 2006, 55 (4): 620-626. Epub 2006/10/03.

10. Hernández, I., Reina-Ortiz, M., Johnson, A., Rosas, C., Sharma, V., Terán, S. et al., “Risk factors associated with hiv among men who have sex with men (msm) in Ecuador”, Am J Men’s Health, 2017, 11(5): 1331-1341.

11. Ali, S.Y., Gajjala, S.R. y Raj, A., “Study of prevalence of dermatophytes among human immunodeficiency virus/ aids patients in Shadan Institute of Medical Sciences and Teaching Hospital and Research Centre, Hyderabad, Telangana, India”, Indian J std and aids, 2018, 39 (2): 98-101.

12. Lahoti, S., Rao, K., Umadevi, H.S. y Mishra, L., “Correlation of mucocutaneous manifestations of hiv-infected patients in an art center with cd4 counts”, Indian J Dental Res, 2017, 28 (5): 549-554.

13. Weitzman, I. y Summerbell, R.C., “The dermatophytes”, Clin Microb Rev, 1995, 8 (2): 240-259.

14. Dahl, M.V. y Grando, S.A., “Chronic dermatophytosis: what is special about Trichophyton rubrum?”, Adv Dermato, 1994, 9: 97-109; discussion: 10-11.

15. Moreno-Coutino, G., Arenas, R. y Reyes-Terán, G., “Improvement in onychomycosis after initiation of combined antiretroviral therapy”, International J Dermatol, 2013, 52 (3): 311-313.

16. Ruiz-López, P., Moreno-Coutino, G., Fernández-Martínez, R., Espinoza-Hernández, J., Rodríguez-Zulueta, P. y Reyes-Terán, G., “Evaluation of improvement of onychomycosis in hiv-infected patients after initiation of combined antiretroviral therapy without antifungal treatment”, Mycoses, 2015, 58 (9): 516-521.

17. Jiménez-González, C., Mata-Marín, J.A., Arroyo-Anduiza, C.I., Ascencio-Montiel, I.J., Fuentes-Allen, J.L. y Gaytán-Martínez, J., “Prevalence and etiology of onychomycosis in the hiv-infected Mexican population”, ejd, 2013, 23 (3): 378-381.

18. Capetti, A. y Rizzardini, G., “Choosing appropriate pharmacotherapy for drug-resistant hiv”, Expert Opinion Pharmacother, 2019, 20 (6): 667-678.

19. Jacobson, J.O., Sánchez-Gómez, A., Montoya, O., Soria, E., Tarupi, W., Chiriboga Urquizo, M. et al., “A continuing hiv epidemic and differential patterns of hiv-sti risk among msm in Quito, Ecuador: an urgent need to scale up hiv testing and prevention”, aids and Behavior, 2014, 18 (1): 88-98.